Advertisement
Singapore markets closed
  • Straits Times Index

    3,471.16
    -18.41 (-0.53%)
     
  • S&P 500

    5,588.27
    -78.93 (-1.39%)
     
  • Dow

    41,198.08
    +243.60 (+0.59%)
     
  • Nasdaq

    17,996.92
    -512.42 (-2.77%)
     
  • Bitcoin USD

    64,595.94
    -590.90 (-0.91%)
     
  • CMC Crypto 200

    1,342.99
    +13.48 (+1.01%)
     
  • FTSE 100

    8,247.90
    +60.44 (+0.74%)
     
  • Gold

    2,466.50
    +6.60 (+0.27%)
     
  • Crude Oil

    82.86
    +0.01 (+0.01%)
     
  • 10-Yr Bond

    4.1460
    -0.0210 (-0.50%)
     
  • Nikkei

    40,126.35
    -971.34 (-2.36%)
     
  • Hang Seng

    17,778.41
    +39.00 (+0.22%)
     
  • FTSE Bursa Malaysia

    1,633.81
    +0.27 (+0.02%)
     
  • Jakarta Composite Index

    7,321.07
    +96.85 (+1.34%)
     
  • PSE Index

    6,705.01
    +17.30 (+0.26%)
     

Monthly information on share capital and company voting rights

Cellectis Inc.
Cellectis Inc.

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, June 05, 2024 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date

Total number of shares
in the capital

Total number of voting rights

05/31/2024

100,093,635

88,029,374

For further information on Cellectis, please contact:

Media contact:

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contacts:

Arthur Stril, Interim Chief Financial Officer, +1 (347) 809 5980, investors@cellectis.com

Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577

Attachment